logo
logo

Sab Biotherapeutics Appoints Michael G. King Jr. As Chief Financial Officer

Sab Biotherapeutics Appoints Michael G. King Jr. As Chief Financial Officer

10/24/23, 11:58 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgmiami
Industry
biotechnology
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

Company Info

Company
SAB Biotherapeutics
Location
777 w 41st st. suite 401
miami, florida, united states
Additional Info
SAB Biotherapeutics (SAB) is a clinical-stage biopharmaceutical company focused on developing fully human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression.

Related People